PE20011028A1 - Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino - Google Patents

Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino

Info

Publication number
PE20011028A1
PE20011028A1 PE2000001196A PE0011962000A PE20011028A1 PE 20011028 A1 PE20011028 A1 PE 20011028A1 PE 2000001196 A PE2000001196 A PE 2000001196A PE 0011962000 A PE0011962000 A PE 0011962000A PE 20011028 A1 PE20011028 A1 PE 20011028A1
Authority
PE
Peru
Prior art keywords
combination
carboplatin
paclitaxel
oncolytic
acethyldinaline
Prior art date
Application number
PE2000001196A
Other languages
English (en)
Inventor
Ronald Lynn Merriman
Wayne Daniel Klohs
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20011028A1 publication Critical patent/PE20011028A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMBINACION DE AGENTES ONCOLITICOS QUE COMPRENDEN a)ACETILDINALINA (4-ACETILAMINO-N-(2'-AMINOFENIL)-BENZAMIDA); b)MONOCLORHIDRATO DE PACLITAXEL Y/O CARBOPLATINO; FORMULADA COMO UNA SOLUCION ESTERIL PARA INFUSION INTRAVENOSA; EL USO DE LOS AGENTES JUNTOS PROPORCIONA UNA EFICACIA MAYOR QUE SI SE EMPLEAN DICHOS AGENTES POR SEPARADO POR LO QUE LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DEL CANCER DE PULMON, PROSTATA, ADENOCARCINOMA LOCALMENTE AVANZADO, QUE NO PUEDE SER RESECCIONADO O METASTASICO DEL PANCREAS
PE2000001196A 1999-11-10 2000-11-09 Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino PE20011028A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16488999P 1999-11-10 1999-11-10
US22256100P 2000-08-03 2000-08-03

Publications (1)

Publication Number Publication Date
PE20011028A1 true PE20011028A1 (es) 2001-10-12

Family

ID=26860956

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001196A PE20011028A1 (es) 1999-11-10 2000-11-09 Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino

Country Status (17)

Country Link
EP (1) EP1229916A2 (es)
JP (1) JP2003513912A (es)
KR (1) KR20020060226A (es)
CN (1) CN1387438A (es)
AR (1) AR026400A1 (es)
AU (1) AU1583201A (es)
CA (1) CA2386876A1 (es)
GT (1) GT200000194A (es)
HU (1) HUP0203153A3 (es)
IL (1) IL149363A0 (es)
NZ (1) NZ518668A (es)
PA (1) PA8506201A1 (es)
PE (1) PE20011028A1 (es)
PL (1) PL355170A1 (es)
SV (1) SV2001000212A (es)
UY (1) UY26431A1 (es)
WO (1) WO2001034131A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
JP5107579B2 (ja) 2003-12-02 2012-12-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 新規の種類のヒストン脱アセチル化酵素阻害剤としてのＺｎ２＋キレートモチーフ係留短鎖脂肪酸
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
EP2322217A3 (en) * 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
PL2415382T3 (pl) 2010-08-06 2013-02-28 Electrolux Home Products Corp Nv Zmywarka nablatowa
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023194441A1 (en) 2022-04-05 2023-10-12 Istituto Nazionale Tumori Irccs - Fondazione G. Pascale Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases

Also Published As

Publication number Publication date
WO2001034131A3 (en) 2002-05-10
HUP0203153A3 (en) 2005-01-28
EP1229916A2 (en) 2002-08-14
AU1583201A (en) 2001-06-06
GT200000194A (es) 2002-05-03
CA2386876A1 (en) 2001-05-17
CN1387438A (zh) 2002-12-25
KR20020060226A (ko) 2002-07-16
PL355170A1 (en) 2004-04-05
UY26431A1 (es) 2000-12-29
PA8506201A1 (es) 2002-12-11
JP2003513912A (ja) 2003-04-15
HUP0203153A2 (hu) 2003-01-28
IL149363A0 (en) 2002-11-10
WO2001034131A2 (en) 2001-05-17
SV2001000212A (es) 2001-10-25
AR026400A1 (es) 2003-02-12
NZ518668A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
PE20011028A1 (es) Combinacion oncolitica de acetildinalina y paclitaxel y/o carboplatino
NO20054988D0 (no) Preparater og metoder for behandling av cancer
AR039416A1 (es) Un metodo para prevenir y/o tratar el rechazo cronico en un organo o un tejido transplantado
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
CY1108070T1 (el) Παραγωγα κινολινονης, ως αναστολεις κινασης τυροσινης
TR200003635T2 (tr) Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
BR0210550A (pt) Método para realçar a eficácia de terapias contra o câncer
ES2097456T3 (es) Conjunto de cateter de succion.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
AR032912A1 (es) Formulacion farmaceutica
CR11486A (es) Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
ES2175179T3 (es) Derivados de bencimidazol sustituidos con naftilo como agentes anticoagulantes.
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
NO20032027L (no) Effektive antitumorbehandlinger
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
AR025449A1 (es) Soluciones farmaceuticas de levosimendan
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
MXPA02012911A (es) Compuestos de rutenio (ii) para el uso en terapia del cancer.
DK0980205T3 (da) Anvendelse af en kombination af TALL-104 celler med adriamycin eller cisplatin i behandlingen af maligniteter
GEP20043239B (en) C10 Carbonate Substituted Taxanes as Antitumor Agents

Legal Events

Date Code Title Description
FD Application declared void or lapsed